BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28534358)

  • 1. Prognostic implications of the intrinsic molecular subtypes in male breast cancer.
    Abdeljaoued S; Lhem B; Nasri M; Adouni O; Goucha GA; Bouzaiene H; Boussen H; Rahal RK; Gamoudi GA
    J BUON; 2017; 22(2):377-382. PubMed ID: 28534358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact.
    Nilsson C; Johansson I; Ahlin C; Thorstenson S; Amini RM; Holmqvist M; Bergkvist L; Hedenfalk I; Fjällskog ML
    Acta Oncol; 2013 Jan; 52(1):102-9. PubMed ID: 22928693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
    Zhu X; Ying J; Wang F; Wang J; Yang H
    Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
    Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
    Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
    Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
    Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of molecular subtype for male breast cancer: a 10-year retrospective study.
    Yu XF; Feng WL; Miao LL; Chen B; Yang HJ
    Breast; 2013 Oct; 22(5):824-7. PubMed ID: 23466329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male breast cancer: Looking for better prognostic subgroups.
    Abreu MH; Afonso N; Abreu PH; Menezes F; Lopes P; Henrique R; Pereira D; Lopes C
    Breast; 2016 Apr; 26():18-24. PubMed ID: 27017238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtyping of male breast cancer by immunohistochemistry.
    Kornegoor R; Verschuur-Maes AH; Buerger H; Hogenes MC; de Bruin PC; Oudejans JJ; van der Groep P; Hinrichs B; van Diest PJ
    Mod Pathol; 2012 Mar; 25(3):398-404. PubMed ID: 22056953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.